[Effect of Venetoclax in the treatment of leukocyte elevation during induction of acute promyelocytic leukemia].
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
A retrospective analysis of clinical data (treatment group) is conducted on the patients of newly diagnosed acute promyelocytic leukemia(APL) who received Venetoclax for increased white blood cells in Linyi People's Hospital from January to December 2024. The patients who received traditional chemotherapy drugs to reduce white blood cells from January 2020 to January 2024 were categorized as the control group. Both groups were followed up to January 1st, 2025. Comparisons were made between groups on white blood cell count reduction time, coagulation recovery, blood transfusion (the infusion volume of platelets, plasma, etc.), courses needed for complete molecular remission (CMR), length of hospital stay, and total cost. A total of 50 patients were included, with 10 patients in the treatment group [4 males and 6 females, aged 19-56 (35±14) years], and 40 patients in the control group [21 males and 19 females, aged 14-76 (45±15) years]. The follow-up time [M (Q1, Q3) ] was 34.9 (10.6, 46.3) months. No statistically significant difference exists between groups in terms of gender, age, white blood cells at diagnosis of APL, disease prognosis stratification, bone marrow promyelocyte proportion, coagulation function indicators, etc (all P>0.05). Compare to the control group, the treatment group exhibited earlier leukocytes reduction [3.0 (2.7, 3.2) vs 4.0 (3.0, 6.0) d] and coagulation recovery [4.5 (1.7, 8.0) vs 7.0 (6.0, 10.0) d], shorter hospital stay [21 (19, 27) vs 28 (25, 29) d], fewer courses for CMR [2.0 (1.8, 2.0) vs 2.5 (2.0, 3.0) times], less need for platelet transfusion (2.5 (1.7, 4.0) vs 4.0 (3.0, 6.0) times], plasma transfusion volumn [100 (0, 250) vs 575 (0, 1 230) ml], and lower cost [2.9 (2.5, 3.8) vs 4.6 (3.5, 6.5) ten thousand yuan] (all P<0.05). The efficacy of Venaclera in reducing the elevation of white blood cells during induction therapy for acute promyelocytic leukemia is still acceptable.